Cardiotoxicity
Drugs: HERCEPTIN
- Safetyreportversion
- 1
- Safetyreportid
- 26940063
- Primarysourcecountry
- CN
- Occurcountry
- CN
- Transmissiondateformat
- 102
- Transmissiondate
- 20260709
- Reporttype
- 2
- Serious
- 1
- Seriousnessdeath
- 2
- Seriousnesslifethreatening
- 2
- Seriousnesshospitalization
- 2
- Seriousnessdisabling
- 2
- Seriousnesscongenitalanomali
- 2
- Seriousnessother
- 1
- Receivedateformat
- 102
- Receivedate
- 20260630
- Receiptdateformat
- 102
- Receiptdate
- 20260630
- Fulfillexpeditecriteria
- 1
- Companynumb
- CN-ROCHE-10000614504
- Primarysource
- Reportercountry
- CN
- Qualification
- 3
- Sender
- Sendertype
- 6
- Senderorganization
- ROCHE
- Receiver
- Receivertype
- 6
- Receiverorganization
- FDA
- Patient
- Patientsex
- 2
- Reaction
- Reactionmeddraversionpt
- 29.0
- Reactionmeddrapt
- Cardiotoxicity
- Reactionoutcome
- 6
- Drug
- Drugcharacterization
- 1
- Medicinalproduct
- HERCEPTIN
- Drugseparatedosagenumb
- 1
- Drugindication
- Invasive ductal breast carcinoma
- Actiondrug
- 5
- Drugrecurreadministration
- 3
- Drugadditional
- 3
- Activesubstance
- Activesubstancename
- TRASTUZUMAB
- Harmonized identifiers (openFDA)
- Application number
- BLA103792
- Brand name
- HERCEPTIN
- Generic name
- TRASTUZUMAB
- Manufacturer name
- Genentech, Inc.
- Product NDC
- 50242-132
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- INTRAVENOUS
- Substance name
- TRASTUZUMAB
- RxCUI
- 1922509, 1922512
- SPL ID
- 7517f775-6a10-4ddd-8dfb-6704ece413d0
- SPL set ID
- 492dbdb2-077e-4064-bff3-372d6af0a7a2
- Package NDC
- 50242-132-01
- Nui
- N0000175661, N0000020008
- Pharm class epc
- HER2/neu Receptor Antagonist [EPC]
- Pharm class moa
- HER2/Neu/cerbB2 Antagonists [MoA]
- UNII
- P188ANX8CK